How should modern analytical development be conducted?
Recommendation

3/4 February 2026
Evaluation, Implementation and Use of Suitable Technologies
In 2017, the board of the ECA Foundation's Analytical Quality Control Group (AQCG) has decided to strengthen the lifecycle approach for analytical procedures. Therefore, the Group developed a new guideline on "Analytical Procedure Lifecycle Management".
The draft for this guideline was discussed with the participants of the Analytical Procedure Lifecycle Management Conference on 23/24 November, 2017 in Vienna. The conference objective was to collect proposals and suggestions for the final version of this guideline. Meanwhile, the ECA QC Group has considered the received suggestions and implemented them as far as possible.
The AQCG is currently in the process of finalizing the final Version 1.0.
In this comprehensive Analytical Procedure Lifecycle Management guideline, the following points are presented and discussed:
- Key References
- Quality involvement/Responsibilities
- Rationale for this Guideline
- Principles of Analytical Procedure Lifecycle Management (APLM)
- Prerequisites for the APLM
- Guidance recommendations for the 3 stages of the APLM
- Stage 1: Procedure Design and Development
- Procedure development and gaining understanding
- Establishing an Analytical Control Strategy
- Establishing a Replication Strategy
- Stage 2: Procedure Performance Qualification
- Stage 3: Procedure Performance Verification
- Technical Glossary
The final Version 1.0 of this guideline will be presented at the ECA APLM Workshop on 20 November 2018 as part of the PharmaLab Congress 2018 in Düsseldorf/Neuss in Germany. Each participant will receive a copy of this important new APLM document, and thereby an important tool for implementing a lifecycle approach to analytical development in one's own company.
Related GMP News
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
18.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
18.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity


